Xcel, Novartis deal

Xcel acquired exclusive U.S. rights to two migraine treatments from NOVN - Migranal dihydroergotamine nasal spray and D.H.E. 45 dihydroergotamine injection. Xcel said proceeds from a $22.5 million ve...